Triangle Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the development of new antiviral drug candidates, with a particular focus on therapies for the human immunodeficiency virus (HIV) and the hepatitis B virus. Triangle's proprietary drug candidates under development for HIV and/or hepatitis B include Coviracil(R) (emtricitabine), amdoxovir (formerly DAPD) and clevudine (formerly L-FMAU). In January 2003, Triangle Pharmaceuticals, Inc. was acquired by Gilead Sciences, Inc. Triangle Pharmaceuticals, Inc. develops new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus. Its portfolio consists of several licensed drug candidates in clinical trials and others that are in a preclinical stage. The company's drug candidates include Coviracil (emtricitabine), a potent nucleoside reverse transcriptase inhibitor in Phase III testing for the treatment of HIV; Amdoxovir, a guanosine nucleoside analogue for the treatment of HIV; and Clevudine, a novel pyrimidine nucleoside analogue for the treatment of chronic Hepatitis B.